| Literature DB >> 24207111 |
Maria M Wertli1, Katrin B Ruchti, Johann Steurer, Ulrike Held.
Abstract
BACKGROUND: Non-cardiovascular chest pain (NCCP) has a high healthcare cost, but insufficient guidelines exist for its diagnostic investigation. The objective of the present work was to identify important diagnostic indicators and their accuracy for specific and non-specific conditions underlying NCCP.Entities:
Mesh:
Year: 2013 PMID: 24207111 PMCID: PMC4226211 DOI: 10.1186/1741-7015-11-239
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Figure 1Study flow.
Baseline characteristic of the studies
| Symptoms suggesting gastroesophageal reflux (GERD)-related non-cardiac chest pain (NCCP) | |||||||
| Kim | Cross-sectional, funding NR | Inpatients with NCCP, referred by a cardiologist after negative cardiac evaluation. Tertiary care, Seoul, Korea. | NCCP was defined when patients were admitted for chest pain to the coronary unit for ≥1 episode of unexplained chest pain/week for ≥3 months. Cardiac chest pain was ruled out by electrocardiogram (ECG), normal enzymes, negative treadmill exercise testing, normal or insignificant ECG changes after intravenous ergonovine injection in coronary angiograms. | Severe liver, lung, renal or hematological disorders. History of peptic ulcer or gastrointestinal (GI) surgery, connective tissue disorder and chest pain originating in a musculoskeletal disorder. | 58 (female 37), NCCP with GERD symptoms (sy) 24, NCCP without GERD sy 34 | 54.6 (10.4) | 17% <6 months, 17% 6 to 12 months, 51% 1 to 5 years, 16% >5 years |
| Hong | Retrospective data analysis, funding NR | Patients with a clinical suspicion of esophageal motility abnormalities and pathological acid exposure within 1 month were included in this analysis. Tertiary care, Seoul, Korea. | Patients with suspicion of esophageal motility abnormalities and pathological acid exposure. NCCP was defined as recurrent angina-like or substernal chest pain believed to be unrelated to the heart, after comprehensive evaluation by the cardiologist. | Obstructive lesions, previous esophageal balloon dilatation, botulism toxin injection, or anti-reflux surgery. No complaints associated with symptoms centered on the esophagus. Connective tissue diseases. | 462 (female 269), dysphagia 53, NCCP 186, GERD sy 117 | 47.6 (10.9) | NR |
| Netzer | Retrospective data analysis, funding NR | First-time referrals to esophageal function testing laboratory. Tertiary care, Bern, Switzerland. | First-time referrals to esophageal function testing laboratory. NCCP group included all patients referred for GI testing because of NCCP. Additional information was obtained by contacting the general practitioner (GP) and interviews. | NR | 303 (female 145), GERD 143, dysphagia 56, NCCP 45 | 50 (15) | NR |
| Mousavi | Prospective observational, funding NR | Outpatient referral by cardiologist after non-invasive diagnostic evaluation and exclusion of a cardiac or other source. Semnan, Iran. | Patients with NCCP referred to the gastrointestinal clinic. NCCP was diagnosed when chest pain was believed to be unrelated to the heart after an evaluation by a cardiologist including non-invasive testing and no apparent other diagnosis was present. | Non-steroidal anti-inflammatory drug (NSAID) use, peptic stricture, duodenal/gastric ulcer. History of upper GI surgery, scleroderma, diabetes mellitus, neuropathy, myopathy or functional bowel disorders, any condition that may affect lower esophageal sphincter pressure or decrease acid clearance time. | 78 (female 37), NCCP with GERD sy. 35, NCCP without GERD 43 | 50.4 (2.3) | 3 to 30 days (mean 9.3 ± 4.2 days) |
| Singh | Retrospective data analysis, funding NR | All consecutive outpatients referred to Esophageal Laboratory for evaluation of upper gastrointestinal complaints. Alabama, USA. | 61 patients had NCCP and were analyzed in comparison to reflux patients for findings in upper gastrointestinal endoscopy and ambulatory 24 h pH monitoring | NR | 153 (female 40) | NR | NR |
| Ho | Cross-sectional, research grant, National University of Singapore | Outpatient referral for NCCP to the gastroenterology service. Tertiary care, Singapore. | Recurrent NCCP ≥3 months. Normal cardiac evaluation (non-obstructed coronary arteries (<50% diameter narrowing), dobutamine stress echocardiography, exercise ECG). Cardiologist evaluation not cardiac. | No history of esophageal disorder or esophageal surgery | 61 (NR) | NR | ≥3 months |
| Lam | Cross-sectional, funding NR | Patients referred to the gastroenterologist after being released from a cardiac care unit (CCU) where they were admitted with suspected myocardial infarction but negative cardiac evaluation. Secondary care, Haarlem, The Netherlands. Patients were eligible for the study when a cardiologist determined the chest pain to be of non-cardiac origin. | Episode of acute, prolonged retrosternal chest pain. Cardiac chest pain was ruled out when no abnormalities on admission ECG, negative results on heart enzyme tests, negative exercise test. Further cardiac testing (coronary angiography) was only performed when considered necessary by the cardiologist. | Age >80 years, ECG ischemic alterations on the admission, arrhythmias, or signs of congestive heart failure | 41 (female 41) | 61.4 (range 40 to 75) | Acute episode of chest pain |
| Studies investigating the efficacy and diagnostic value of proton pump inhibitor (PPI) trials in GERD-related NCCP | |||||||
| Dickman | Randomized, controlled trial (RCT), double-blind, crossover, Janssen Pharmaceutica und Eisai Inc. | Outpatient referral by a cardiologist after negative cardiac evaluation. Tertiary care, Arizona, USA. | NCCP ≥3 episodes/week (angina-like) for ≥3 months. Normal/insignificant findings coronary angiogram, or insufficient evidence for ischemic heart disease (IHD) in non-invasive tests. | Severe comorbidity, previous empirical anti-reflux regimen, history of peptic ulcer disease or gastrointestinal surgery | 35 (female 12), GERD + 16 (45.7%), GERD- 19 (54.3%) | 55.6 (10.10) | ≥3 months |
| Bautista | RCT, double-blind, crossover, TAP Pharmaceuticals | Outpatient referral by a cardiologist after negative cardiac evaluation. Tertiary care, Arizona, USA. | NCCP ≥3 episodes (angina-like) for ≥3 months. Normal/insignificant findings coronary angiogram, or insufficient evidence for IHD in non-invasive tests. | Severe comorbidity, previous empirical anti-reflux regimen, history of peptic ulcer disease or gastrointestinal surgery | 40 (female 9), placebo 40, GERD + 18, GERD- 22 | 54.4 (2.78) | ≥3 months |
| Fass | RCT, double-blind, crossover, Astra-Merck research grant | Outpatient referral by a cardiologist after negative cardiac evaluation. Tertiary care, Arizona, USA. | NCCP ≥3 episodes (angina-like) for ≥3 months. Normal/insignificant findings coronary angiogram, or insufficient evidence for IHD in non-invasive tests. | Previous empirical anti-reflux regimen, history of peptic ulcer disease or gastrointestinal surgery | 37 (female 1), GERD + 23, GERD- 14 | 58.2 (2.3) | ≥3 months |
| Pandak | RCT, double-blind, crossover, Astra Zeneca | Patients presented with recurrent chest pain, whose chest pain was determined by cardiologist to be of non-cardiac origin with the aid of methoxyisobutylisonitrile (MIBI) testing. Tertiary care, Arizona, USA. | Unexplained recurrent chest pain determined to be of non-cardiac origin by a cardiologist and had negative results on MIBI testing | Previous empirical anti-reflux regimen, gastric or duodenal ulcer, prior gastric surgery, abnormalities on physical exam or chest x-ray that would explain the chest pain | 42 (female 24), GERD + 20, GERD- 18 | Range 22 to 77 | ≥6 months |
| Kim | Prospective observational, Janssen Pharmaceuticals | Inpatients referred after negative cardiac examination by cardiologists to gastroenterology. Tertiary care, Seoul, Korea. | NCCP was defined when patients were admitted for chest pain to the coronary unit for ≥1 episode of unexplained chest pain/week for ≥3 months. Cardiac chest pain was ruled out by ECG, normal enzymes, negative treadmill exercise testing, normal or insignificant ECG changes after intravenous ergonovine injection in coronary angiograms. | Severe comorbidity, history of peptic ulcer disease or gastrointestinal surgery, history of connective tissue disorder and chest pain originating from musculoskeletal disorder | 42 (female 17), GERD + 16, GERD- 26 | 53.9 (12.8) | ≥3 months: n = 12 3 to 12 months; n = 23 1 to 5 years; n = 7 >5 years |
| Xia | RCT, single blind, Simon KY Lee Gastroenterology Research Fund | Referred by a cardiologist after negative cardiac evaluation. Tertiary care, Hong Kong, China. | NCCP ≥12 weeks during last 12 months. Normal coronary angiograph, chest pain considered by a cardiologist to be NCCP. | Pathologic endoscopic finding, previous anti-reflux regimen, apparent heartburn, acid reflux, dysphagia and dyspepsia | 68 (female 42), placebo 32, lansoprazole 36 | 58.2 (10.0) | ≥12 weeks |
| Kushnir | Retrospective data analysis, Mentors in Medicine, Washington University, St Louis, MO, USA | Outpatients referred for ambulatory pH monitoring for the evaluation of unexplained chest pain. Tertiary care, Missouri, USA. | Unexplained chest pain. Cardiac causes were excluded in all instances before referral. | Anti-reflux surgery in the past, chest pain was not the dominant symptom, pH manometry data incomplete | 98 (female 75) | 51.8 (1.1) | 7.4 ± 4.1 years |
| Lacima | Cross-sectional, funding NR | Referred by a cardiologist after negative cardiac evaluation. Barcelona, Spain. | Normal ECG, cardiac enzymes, treadmill exercise testing, coronary angiography and epicardial coronary arteries or with <25% narrowing, no ECG changes after intravenous ergonovine injection | Previous anti-reflux regimen, calcium channel blockers, beta blockers and/or nitrates were withdrawn at least 7 days before the study | 120 (female 62), patients 90, volunteers 30 | 57 (27 to 82) | NR |
| Studies investigating the value of provocation tests for the diagnosis of GERD-related NCCP | |||||||
| Cooke | Cross-sectional, funding NR | Patients in whom coronary angiography was performed for the diagnosis of new chest pain. Secondary care, London, UK. | New chest pain and normal coronary anatomy with exertional pain as principal complaint | Mitral valve prolapse, left ventricular hypertrophy, previous myocardial infarction, abnormalities of resting wall motion on echocardiography, pain at rest only, unable to exercise. Previous anti-reflux regimen, previous gastroenterologist assessment. | 66 (female 34), non-cardiovascular disease (CVD) 50, CVD 16 (controls) | 53 (non-CVD), CVD 58, range 32 to 72 | 3.4 years |
| Bovero | Cross-sectional, funding NR | Patients investigated for chest pain. Secondary care, Genova, Italy. | Chest pain, no coronaroactive drugs for ≥5 days. No anti-reflux regimen ≥3 days. | Chest pain of organic and/or functional cardiologic origin (evaluated by: ECG, two ergometry tests, dynamic ECG, thallium myocardial scintigraphy under physical stress or echodypiridamole test, ergonovine or methyl-ergometrine test, angiography) | 67 (female 43), pain at rest 46, exertional pain 21 | 53 (range 34 to 76) | NR |
| Romand | Cross-sectional, funding NR | Referred after negative cardiac evaluation. Secondary care, Lyon, France. | Normal coronary anatomy, normal ECG, negative treadmill exercise | Cardiologic origin of symptoms, history of upper gastrointestinal surgery, duodenal or gastric ulcer, peptic stricture or stricture by a tumor | 43 (female 19) | 56 (range 31 to 78) | n = 25 <1 year; n = 7 1 to 5 years; n = 11 >5 years |
| Abrahao | Cross-sectional, funding NR | Referred by a cardiologist after negative cardiac evaluation. Tertiary care, Rio de Janeiro, Brazil. | ≥1 episode of NCCP/week, normal coronary angiogram or with <30% narrowing | Chronic obstructive lung disease, asthma, cardiac arrhythmia, cardiomyopathy, valvular heart disease | 40 (female 32) | 54.7 (8.4) | Mean 24 months (range 1 to 360 months) |
| Ho | Cross-sectional, research grant from the National University of Singapore | Referred for NCCP to the gastroenterology service, Singapore | Recurrent chest pain of ≥3 months; cardiologists evaluation normal and symptoms not cardiac (non-obstructed coronary arteries (<50% luminal narrowing), dobutamine stress echocardiography, exercise ECG) | No history of proven esophageal disorder or esophageal surgery | 80 (female 38) | 48 (range 21 to 75) | ≥3 months |
| Eosinophilic esophagitis-related NCCP | |||||||
| Achem | Retrospective data analysis, funding NR | Referred for endoscopic evaluation of NCCP, who had esophageal biopsies for suspected eosinophilic esophagitis. Secondary care, Florida, USA. | Chest pain suspected of being esophageal origin after negative cardiac evaluation (either by non-invasive stress testing or coronary angiography) | Dysphagia (if this was the main reason for endoscopy). Anticoagulant use. | 171 (female 104), 24 (female 7) eosinophilia, 147 (female 97) normal histology | 59 (24 to 86) normal histology, 55 (21 to 81) eosinophilia | NR |
| Musculoskeletal NCCP | |||||||
| Stochkendahl | Cross-sectional, Foundation Chiropractic Research and Postgraduate Education, Government | Patients discharged form an emergency cardiology department. Tertiary care, Odense, Denmark. | Acute (<7 days) chest pain primary complaint. Pain in the thorax and/or neck. Understand Danish. Age 18 to 75 years, resident of the Funen County. | Cardiovascular disease, previous percutaneous coronary intervention or coronary artery bypass graft: other definite cause, inflammatory joint disease, insulin dependent diabetes, fibromyalgia, malignant disease, apoplexy, dementia or unable to cooperate, major osseous anomaly, osteoporosis, pregnancy | 302 (female 132) | 52.5 (11.0) | Acute episode, <7 days before admission |
| Bosner | Cross-sectional with 6 months follow-up, federal Ministry of Education and Research grant | Consecutive recruitment of all patients presenting to chest pain in a GP clinic. An independent interdisciplinary reference panel decided about the etiology of chest pain. | Age >35 years, pain (acute or chronic) localized between clavicles and lower costal margins and anterior to the posterior axillary lines | Patients whose chest pain had been investigated already and/or who came for follow-up for previously diagnosed chest pain were excluded | 1,212 (female 678), chest wall symptom (CWS) 565 (female 330) | All 59 (35 to 93), CWS 58 (35 to 90) | Acute pain 28.4% |
| Manchikanti | Cross-sectional, no funding | Chronic thoracic pain, managed by one physician and undergoing diagnostic medial branch blocks. Private pain practice, USA. | Pain for ≥6 months. Failure of conservative management with physical therapy, chiropractic management and drug therapy. Age 18 to 90 years. | No radicular pattern of pain, no disc herniation on MRI | 46 (female 31) | 46 (2.2) | ≥6 months, mean 86 (SD 17.2) months |
| NCCP related to psychiatric diseases | |||||||
| Kuijpers | Cross-sectional, funding NR | Discharged from the hospitals first-heart-aid service with a diagnosis of NCCP received an envelope | Chest pain or palpitation presenting to first-heart-aid service, received no cardiac explanation | Dementia, live ≥50 km from the hospital. Do not speak Dutch. | 344 (female 151), Hospital Anxiety Depression Scale (HADS) ≥8: 266 (female 123); HADS <8: 78 (female 28) | HADS ≥8: 55.81 (13.03); HADS <8: 60.55 (10.84) | NR |
| Demiryoguran | Cross-sectional, funding NR | Patients admitted to the ER and discharged with a diagnosis of NCCP. Ismir, Turkey. | Cardiac chest pain ruled out. Normal ECGs and low or stable levels of cardiac markers. | Unstable vital signs, uncooperative and disoriented patients. Established diagnoses. Documented coronary artery disease, history of trauma to chest wall, back or abdomen within the previous week. | 157 (female 89), HADS <10: 108 (female 55), HADS >10: 49 (female 34) | 41.6 (11.7) | NR |
| Foldes-Busque | Cross-sectional, Groupe interuniversitaire de recherche sur les urgences (GIRU) and Fonds de Recherche en Santé du Québec | Emergency department (ED), Monday to Friday between 8 AM and 4 PM. Tertiary care, Quebec, Canada. | Low-risk unexplained chest pain, ≥18 years old. English or French speaking, normal serial ECG, normal cardiac enzymes. | Explained chest pain (for example, ischemic, cause identifiable by radiography). Medical condition that could invalidate the interview (for example, psychosis, intoxication, or cognitive deficit), any unstable condition, or any trauma. | 507 (NR), derivation sample 201 (female 101); validation sample 306 (female 173) | Derivation condition 54.2 (13.9), validation condition 53.3 (14.4) | NR |
| Fleet | Cross-sectional, Fonds de Recherché en Santé Québec | Consecutive patients presenting to ambulatory walk in ED, patients with or without IHD, Québec, Canada | Complaint of chest pain, understand French, able to complete evaluation in the ED | Cognitive impairment, psychotic state | Derivation sample 180 (female 63), validation sample 212 | Development 57.6 (12.6), validation 56 (12.2) | NR |
| Katerndahl | Cross-sectional, public health and service Establishment of Departments of Family Practice | Presented to the GP with a chief compliant of new-onset chest pain. Primary care, Texas, USA. | Adults 18 years and older, new-onset chest pain, only one complaint (chest pain) as well as those with several symptoms that included chest pain | Previous investigation for chest pain at the practice | 51 (NR) | 42.6 (14.6) | New onset |
NR not reported.
Summary of diagnostic accuracy of tests used in non-cardiac chest pain
| | | | | | |
|---|---|---|---|---|---|
| Symptoms | |||||
| Kim | NCCP with atypical GERD symptoms | Endoscopy (LA classification) and/or 24 h pH-metry (>4%, pH <4 | 24 | 0.49 | 2.71 |
| Kim | NCCP with typical GERD symptoms | Same | 67 | 2.75 | 0.42 |
| Mousavi | NCCP with typical GERD symptoms | GERD if two tests positive: endoscopy (Hentzel-Dent), Bernstein test, omeprazole trial | 45 | 2.70 | 0.78 |
| Mousavi | NCCP relieved by antacid | Same | 45 | 0.51 | 3.51 |
| Mousavi | NCCP and heartburn in past history | Same | 45 | 2.15 | 0.74 |
| Mousavi | NCCP and regurgitation in past history | Same | 45 | 2.98 | 0.61 |
| Hong | NCCP | Manometry (Specler 2001 criteria) and/or 24 h pH-metry (>4% pH <4) | 43 | 0.83 | 1.13 |
| Hong | Control: dysphagia | Same | 45 | 1.27 | 0.97 |
| Hong | Control: GERD-typical symptoms | Same | 44 | 1.26 | 0.93 |
| Netzer | NCCP | Manometry and/or 24 h pH-metry (>10.5% pH <4) | 84 | 0.43 | 1.23 |
| Netzer | Control: GERD-typical symptoms | Same | 84 | 1.53 | 0.74 |
| Netzer | Control: dysphagia | Same | 84 | 1.16 | 0.97 |
| Proton pump inhibitor (PPI) trial | |||||
| Dickman | Rabeprazole 20 mg twice a day for 1 week SIS ≥50% | Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry (>4.2% pH <4) | 46 | 7.13 | 0.28 |
| Dickman | Placebo for 1 week | Same | 46 | 0.89 | 1.03 |
| Bautista | Lansoprazole 60 mg AM, 30 mg PM for 1 week SIS ≥50% | Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry (>4.2% pH <4) | 45 | 8.56 | 0.24 |
| Bautista | Lansoprazole 60 mg AM, 30 mg PM for 1 week SIS ≥65% | Same | 45 | 18.33 | 0.17 |
| Bautista | Placebo for 1 week | Same | 45 | 0.61 | 1.22 |
| Fass | Omeprazole 40 mg AM, 20 mg PM for 1 week SIS ≥50% | Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry (>4.2% pH <4) | 62 | 5.48 | 0.25 |
| Fass | Placebo for 1 week | Same | 62 | 3.04 | 0.84 |
| Pandak | Omeprazole 40 mg twice a day for 2 weeks SIS ≥50% | Endoscopy and/or 24 h pH-metry (>4.2% pH <4) | 53 | 2.70 | 0.15 |
| Pandak | Placebo for 2 weeks SIS ≥50% | Same | 53 | 0.30 | 1.14 |
| Kim | NCCP rabeprazole for 1 week SIS ≥50% | Endoscopy (LA classification) and/or 24 h pH-metry (>4.0 pH <4) | 38 | 2.17 | 0.65 |
| Kim | NCCP rabeprazole for 2 weeks SIS ≥50% | Same | 38 | 3.02 | 0.26 |
| Xia | Lansoprazole 30 mg once a day for 4 weeks SIS ≥50% | 24 h pH-metry (De Meester pH <4, 7.5 s) | 33 | 2.75 | 0.13 |
| Xia | Placebo for 4 weeks SIS ≥50% | Same | 38 | 0.95 | 1.03 |
| Kushnir | High-degree response on PPI (not specified) | 24 pH-metry (≥4%, pH <4) | 53 | 1.97 | 0.38 |
| Provocation test | | | | | |
| Cooke | NCCP during exertional pH-metry | 24 h pH-metry (5.5% pH <4 for 10 s) | 38 | 14.40 | 0.79 |
| Cooke | Control group: CVD with angina: exertional pH-metry | Same | 19 | 4.33 | 0.72 |
| Bovero | NCCP with normal ECG during exertional pH-metry | 24 h pH-metry (De Meester criteria: >4.5% pH <4)) | 69 | 7.76 | 0.66 |
| Bovero | NCCP at rest: NCCP with normal ECG during exertional pH-metry | Same | 74 | 3.88 | 0.74 |
| Bovero | NCCP exertion/mixed: NCCP with normal ECG during exertional pH-metry | Same | 57 | 10.00 | 0.50 |
| Romand | NCCP: pH <4 for 10 s during exertional pH-metry | 24 h pH-metry (De Meester criteria: >4.5% pH <4)) | 23 | 1.65 | 0.52 |
| Abrahao | NCCP reproducible during balloon distension | Endoscopy (Savary-Miller) and/or manometry and/or pH-metry (De Meester criteria: >4.5% pH <4 | 88 | 2.00 | 0.75 |
| Abrahao | NCCP reproducible during Tensilon test | Same | 88 | 0.43 | 1.38 |
| Abrahao | NCCP reproducible during Bernstein test | Same | 88 | 1.29 | 0.93 |
| Abrahao | Tensilon and Bernstein Test and balloon distension (+ if 1 test +) | Same | 88 | 0.95 | 1.07 |
| Ho | NCCP reproducible during Bernstein test | 24 h pH-metry (>4% pH <4, 4 s) | 23 | 0.75 | 1.06 |
| Musculoskeletal disorders | | | | | |
| Stochkendahl | ≥3 of 5 palpation findings: (1) sitting motion of end-play restriction in lateral flexion and rotation segment C4 to C7 and Th1 to Th8. (2) Prone motion joint-play restriction segment Th1 to Th8. (3) Prone evaluation paraspinal tenderness segment Th1 to Th8. (4) Supine manual palpation muscular tenderness of 14 points anterior chest wall. 5) Supine evaluation of tenderness of the costosternal junctions of costa 2 to 6 and xiphoid process | Diagnosis using a standardized examination protocol: | 37 | 1.52 | 0.03 |
| (1) A semistructured interview: pain characteristics, lung and gastrointestinal symptoms, past medical history, height, weight, cardiovascular risk factors | |||||
| (2) A general health examination: blood pressure, pulse, heart and lung stethoscopy, abdominal palpation, neck auscultation, signs of left ventricular failure, neurological examination | |||||
| (3) Manual examination of the muscles and joints (neck, thoracic spine and thorax): active range of motion, manual palpation 14 points muscular tenderness of the anterior chest wall and segmental paraspinal muscles, motion palpation for joint-play restriction of the thoracic spine (Th1 to 8), and end play restriction of the cervical and thoracic spine | |||||
| Bosner | Chest wall symptom (CWS) score: localized muscle tension, stinging pain, pain reproducible by palpation, absence of cough | Interdisciplinary consensus: cardiologist, GP, research associate (based on reviewed baseline, follow-up data at 6 weeks and 6 months) | 47 | 1.82 | 0.20 |
| Cut-off test negative 0 to 1 points | |||||
| Bosner | CWS score: localized muscle tension, stinging pain, pain reproducible by palpation, absence of cough | Interdisciplinary consensus | 47 | 3.02 | 0.47 |
| Cut-off test negative 0 to 2 points | |||||
| Stochkendahl | Biomechanical dysfunction (part of the standardized examination protocol)a | Standardized examination protocol | 37 | 1.58 | 0.00 |
| Stochkendahl | Anterior chest wall tenderness | Standardized examination protocol | 37 | 1.39 | 0.06 |
| Stochkendahl | Angina pectoris (uncertain or negative) | Standardized examination protocol | 37 | 1.26 | 0.12 |
| Stochkendahl | Pain worse on movement of torso | Standardized examination protocol | 37 | 3.39 | 0.78 |
| Bosner | Pain worse with movement | Interdisciplinary consensus | 47 | 2.13 | 0.75 |
| Stochkendahl | Positive/possible belief in pain origin from muscle/joints | Standardized examination protocol | 37 | 1.17 | 0.20 |
| Stochkendahl | Pain relief on pain medication | Standardized examination protocol | 37 | 3.26 | 0.83 |
| Bosner | Pain reproducible by palpation | Interdisciplinary consensus | 47 | 2.08 | 0.54 |
| Stochkendahl | Paraspinal tenderness | Standardized examination protocol | 37 | 1.36 | 0.48 |
| Bosner | Localized muscle tension | Interdisciplinary consensus | 47 | 2.41 | 0.52 |
| Stochkendahl | Chest pain present now | Standardized examination protocol | 37 | 1.35 | 0.46 |
| Bosner | Pain now | Interdisciplinary consensus | 47 | 1.15 | 0.85 |
| Stochkendahl | Pain debut not during a meal | Standardized examination protocol | 37 | 1.10 | 0.23 |
| Stochkendahl | Sharp pain | Standardized examination protocol | 37 | 1.89 | 0.80 |
| Bosner | Stinging pain | Interdisciplinary consensus | 47 | 1.87 | 0.66 |
| Stochkendahl | Hard physical exercise at least once a week | Standardized examination protocol | 37 | 1.19 | 0.91 |
| Stochkendahl | Pain not provoked during a meal | Standardized examination protocol | 37 | 1.09 | 0.25 |
| Stochkendahl | Not sudden debut | Standardized examination protocol | 37 | 2.90 | 0.63 |
| Bosner | Pain >24 h | Interdisciplinary consensus | 47 | 1.30 | 0.92 |
| Stochkendahl | Age ≤49 years old | Standardized examination protocol | 37 | 2.10 | 0.56 |
| Bosner | Pain mostly at noon time | Interdisciplinary consensus | 47 | 0.50 | 1.02 |
| Bosner | Cough | Interdisciplinary consensus | 47 | 0.28 | 1.18 |
| Bosner | Known IHD | Interdisciplinary consensus | 47 | 0.52 | 1.11 |
| Bosner | Pain worse with breathing | Interdisciplinary consensus | 47 | 1.28 | 0.93 |
| Psychiatric diseases | | | | | |
| Kuijpers | Anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A score, cut-off ≥8) | Diagnosis anxiety disorders (Mini International Neuropsychiatric Interview (gold standard)) | 58 | 2.03 | 0.03 |
| Demiryoguran | Chills or hot flushes | Anxiety disorder: HADS-A score (cut-off ≥10) | 31 | 4.85 | 0.81 |
| Demiryoguran | Fear of dying | Anxiety disorder: HADS-A score (cut-off ≥10) | 31 | 4.04 | 0.82 |
| Demiryoguran | Diaphoresis | Anxiety disorder: HADS-A score (cut-off ≥10) | 31 | 3.49 | 0.69 |
| Demiryoguran | Light-headedness, dizziness, faintness | Anxiety disorder: HADS-A score (cut-off ≥10) | 31 | 3.03 | 0.84 |
| Demiryoguran | Palpitation | Anxiety disorder: HADS-A score (cut-off ≥10) | 31 | 1.54 | 0.83 |
| Demiryoguran | Shortness of breath | Anxiety disorder: HADS-A score (cut-off ≥10) | 31 | 1.30 | 0.92 |
| Demiryoguran | Nausea or gastric discomfort | Anxiety disorder: HADS-A score (cut-off ≥10) | 31 | 1.98 | 0.90 |
| Foldes-Busque | The Panic Screening Score (derivation population); does the patient have a history of anxiety disorders? Please indicate how often this thought occurs when you are nervous: ‘I will choke to death’. Did the patient arrive in the ED by ambulance? Please answer the statement by circling the number that best applies to you: ‘When I notice my heart beating rapidly, I worry that I might be having a heart attack’. Sum score 22, A total score ≥6 indicates probable panic. | Panic disorder Diagnosis (structured Anxiety Disorders Interview Schedule for | 42 | 3.89 | 0.44 |
| Foldes-Busque | The Panic Screening Score (validation population). | Panic disorder diagnosis (structured ADIS-IV) | 43 | 3.44 | 0.55 |
| Fleet | Panic disorder diagnosis: formula including Agoraphobia Cognitions QA, Mobility Inventory for Agoraphobia, Zone 12 Dermatome Pain Map, Sensory McGill Pain QA, Gender, Zone 25 (validation population) | Panic disorder (ADIS-R structured interview by psychologist) | 23 | 2.60 | 0.46 |
| Katerndahl | GP diagnosis of panic disorder | Panic disorder (structured clinical interview of | 55 | 0.82 | 1.02 |
LR+: >10; LR-: <0.1; good: LR + 5 to 10, LR- 0.1 to 0.2; fair: LR + 2 to 5, LR- 0.2 to 0.5; poor: LR + 1 to 2, LR- 0.5 to 1.
aBiomechanical dysfunction defined as chest pain presumably caused by mechanical joint and muscle dysfunction related to C4 to Th8 somatic structures of the spine and chest wall established by means of joint-play and/or end-play palpation.
Reference tests are as follows. Endoscopic classification: LA classification: grade A, ≥1 mucosal break ≤5 mm, that does not extend between the tops of two mucosal folds; grade B, ≥1 mucosal break >5 mm long that does not extend between the tops of two mucosal folds; grade C, ≥1 mucosal break that is continuous between the tops of two or more mucosal folds but which involves <75% of the circumference; grade D, ≥1 mucosal break which involves at least 75% of the esophageal circumference [52]. Savary-Miller system: grade I, single or isolated erosive lesion(s) affecting only one longitudinal fold; grade II multiple erosive lesions, non-circumferential, affecting more than one longitudinal fold, with or without confluence; grade III, circumferential erosive lesions; grade IV, chronic lesions: ulcer(s), stricture(s) and/or short esophagus. Alone or associated with lesions of grades 1 to 3; grade V, columnar epithelium in continuity with the Z line, non-circular, star-shaped, or circumferential. Alone or associated with lesions of grades 1 to 4 [53]. Hentzel-Dent grades: grade 0, no mucosal abnormalities; grade 1, no macroscopic lesions but erythema, hyperemia, or mucosal friability; grade 2, superficial erosions involving <10% of mucosal surface of the last 5 cm of esophageal squamous mucosa; grade 3, superficial erosions or ulceration involving 10% to 50% of the mucosal surface of the last 5 cm of esophageal squamous mucosa; grade 4, deep peptide ulceration anywhere in the esophagus or confluent erosion of >50% of the mucosal surface of the last 5 cm of esophageal squamous mucosa [54]. pH-metry: De Meester criteria: (1) total number of reflux episodes; (2) number of reflux episodes with pH <4 for more than 5 minutes; (3) duration of the longest episode; (4) percentage total time pH <4; (5) percentage upright time pH <4; and (6) percentage recumbent time pH <4. [55]. Manometry: Spechler criteria is diagnosis of ineffective esophageal motility, nutcracker esophagus, spasm, achalasia based on basal lower esophageal sphincter pressure, relaxation, wave progression, distal wave amplitude [56].
24-h pH-metry 24-h pH monitoring, GERD gastroesophageal reflux disease, GP general practitioner, IHD ischemic heart disease, QA questionnaire, Sensory McGill McGill Pain Questionnaire sensory subscale, SIS symptom index score calculated by adding the reported daily severity (mild = 1; moderate = 2; severe = 3; and disabling = 4) multiplied by the reported daily frequency values during each week).
Figure 2Summary receiver operating characteristic (ROC) curve of proton pump inhibitor (PPI) studies.
Figure 3Summary receiver operating characteristic (ROC) for treadmill test during 24 h pH-metry.
Search Strategy May Week 4 2012 (PubMed)
| 1 | Search thoracic pain OR chest pain OR noncardiac chest pain OR non cardiac chest pain OR atypical chest pain OR musculoskeletal chest pain OR esophageal chest pain OR thoracic spine pain OR chest wall | 96,313 |
| 2 | Search coronary artery disease OR cardiac disease OR coronary heart disease OR coronary thrombosis OR coronary occlusion | 929,959 |
| 3 | Search 1 NOT 2 | 38,735 |
| 4 | Search sensitivity OR specificity OR diagnostic tests OR chest pain/diagnosis | 1,301,595 |
| 5 | Search 3 AND 4 | 2,736 |
| 6 | Search 5 NOT 2; Filters: publication date from 1992/01/01; humans | 2,177 |
| 7 | Search 5 NOT 2; Filters: publication date from 1992/01/01; humans; adult: 19+ years | 1,432 |
Database: PsycINFO <1806 to May Week 4 2012>, Embase <1974 to 2012 Week 21> (OvidSP)
| 1 | (thoracic pain or chest pain or noncardiac chest pain or non cardiac chest pain or atypical chest pain or musculoskeletal chest pain or esophageal chest pain or thoracic spine pain or chest wall).mp. [mp = ti, ab, hw, tc, id, ot, tm, sh, tn, dm, mf, dv, kw] | 44,196 |
| 2 | exp thorax pain/di [Diagnosis] | 2,481 |
| 3 | exp thorax pain/ | 36,580 |
| 4 | 1 or 3 | 63,756 |
| 5 | Coronary artery disease or cardiac disease or coronary heart disease or coronary thrombosis or coronary occlusion).mp. [mp = ti, ab, hw, tc, id, ot, tm, sh, tn, dm, mf, dv, kw] | 222,468 |
| 6 | 4 not 5 | 55,961 |
| 7 | (sensitivity or specificity or diagnostic tests).mp. [mp = ti, ab, hw, tc, id, ot, tm, sh, tn, dm, mf, dv, kw] | 1,162,714 |
| 8 | 2 or 7 | 1,164,908 |
| 9 | 6 and 8 | 4,565 |
| 10 | Limit 9 to human | 4,180 |
| 11 | Limit 10 to year = ‘1992-Current’ | 3,778 |
| 12 | Limit 11 to ‘300 adulthood < age 18 years and older > ‘ [Limit not valid in Embase; records were retained] | 3,769 |
| 13 | Limit 12 to adulthood <18+ years > [Limit not valid in Embase; records were retained] | 3,769 |
Summary of excluded studies during full-text review
| Aanen | 2008 | cohort, prospective | No diagnostic study. No NCCP. GERD, reproducibility of reflux symptoms only |
| Abbass | 2009 | randomised clinical trial | No diagnostic study. No NCCP. General pain patients |
| Achem | 1993 | retrospective, review | Prevalence of nutcracker esophagus in NCCP. For treatment outcome open label trial with small sample |
| Achem | 1997 | randomised, controlled trial | No diagnostic study. GERD patients only received PPI |
| Achem | 2000 | review article | Review article about atypical chest pain |
| Adams | 2001 | retrospective review | no NCCP. Spiral CT in pulmonary embolism |
| Adamek | 1995 | cross-sectional study | No reference test. Description of coexistence of motility disorders and pathologic acid reflux |
| Aikens | 2001 | cross-sectional study | No diagnostic study, presence of fear in NCCP patients. Correlation of fear with symptoms |
| Aizawa | 1993 | cross-sectional study | no NCCP, acetylcholine provocation test for coronary arterial spasm |
| Ajanovic | 1999 | cross-sectional study | no NCCP. Pulmonary embolism |
| Aksglaede | 2003 | experimental | Experimental. Small sample (n = 5) chest pain. |
| Alexander | 1994 | cross-sectional study | Prevalence and nature of mental disorders in NCCP and IHD |
| Amarasiri | 2010 | cross-sectional study | GERD patients not NCCP |
| Anzai | 2000 | cross-sectional study | No reference test, coronary flow reserve with dopler in patients with no significant coronary stenosis |
| Armstrong | 1992 | review article | Review article about atypical chest pain |
| Arnold | 2009 | randomised clinical trial | No diagnostic study. Treatment outcome |
| Aufderheide | 1996 | validation | Validation of ACI-TIPI probabilities for MI |
| Bak | 1994 | cohort, prospective | No diagnostic study. Comparison of prevalence of findings |
| Balaban | 1999 | experimental | No diagnostic study. Small sample (n = 10) |
| Baniukiewicz | 1997 | cross-sectional study | No diagnostic study. Description of findings in upper GI studies |
| Barham | 1997 | observational | No NCCP. Description of presence of esophageal spasm in patients undergoing upper GI studies |
| Barki | 1996 | cohort, prospective | No diagnostic study. Description of clinical presentation in painful rip syndrome |
| Basseri | 2011 | experimental | Experimental. No NCCP. Different techniques swallow studies |
| Bassotti | 1998 | cohort, retrospective | No NCCP. Nutcracker esophagus and the symptoms and findings investigated. |
| Bassotti | 1992 | cohort, prospective | No diagnostic study. Prevalence |
| Beck | 1992 | cross-sectional study | No diagnostic study. Charasteristics of NCCP patients compared to general pain patients |
| Belleville | 2010 | cross-sectional study | No diagnostic study. Characteristics of patients with panic disorders in the ER |
| Berkovich | 2000 | cohort, retrospective | No NCCP |
| Bernstein | 2002 | validation | GOLDmineR: improvement of a risk model |
| Berthelot | 2005 | cohort, retrospective | No diagnostic study. Pain referral study after injection |
| Bjorksten | 1999 | cross-sectional study | No patients, workers with muscoloskeletal complaints |
| Blatchford | 1999 | cross-sectional study | No NCCP. Emergency medical admission rates |
| Borjesson | 1998 | cross-sectional study | Small sample (n = 18), prevalence of esophageal findings |
| Borjesson | 1998 | non-randomised controlled trial | No diagnostic study. Small sample size (n = 20 per group). Intervention = TENS |
| Bortolotti | 2001 | experimental | No diagnostic study, small sample (n = 9) |
| Bortolotti | 1997 | randomised clinical trial | No diagnostic study. L-Arginine in patients with NCCP. Small sample (n = 8) |
| Bovero | 1993 | cohort, prospective | Duplicate of same study Bovero 1993 included in the analysis under different titel |
| Bovero | 1993 | cohort, prospective | Duplicate of same study Bovero 1993 included in the analysis under different titel |
| Brims | 2010 | review article | Review article about atypical chest pain |
| Broekaert | 2006 | experimental | Experimental trial in volunteers (no patients, n = 10) |
| Brunse | 2010 | cohort, prospective | No diagnostic study. Prevalence |
| Brusori | 2001 | cross-sectional study | Mixed sample, diagnosis of esophageal dysmotility in fluoroscopy vs. Manometry |
| Budzynski | 2010 | cross-sectional study | Mixed patients sample with significant and non significant coronary leasons not responding to PPI treatment |
| Bruyninckx | 2009 | cross-sectional study | No diagnostic study. GP's reasons for referral |
| Cameron | 2006 | case series | Case series, selected sample by gastroenterologist. Not all patients had all investigation. Small samples for each group |
| Cannon | 1994 | randomised clinical trial | Treatment outcome (imipramine vs. placebo) |
| Carter | 1997 | review article | Review article about atypical chest pain |
| Cremonini | 2005 | review article | Systematic Review PPI |
| Castell | 1998 | Editorial | Editorial |
| Chambers | 1998 | observational | Small sample size: n = 23, SI in 7 patients not calculated |
| Cheung | 2007 | cross-sectional study | No diagnostic study. Questionnaire to doctors to see what kind of patients they see, what diagnostic tests they use and how they treat. |
| Christenson | 2004 | cohort, prospective | Chest discomfort inappropriately not diagnosed ACS. Different research question |
| Crichton | 1997 | experimental | Experimental statistical rule out |
| Cossentino | 2012 | randomised clinical trial | No diagnostic study. Baclofen in gastro-esophageal diseases |
| Dekel | 2003 | cohort, retrospective | No diagnostic study. Prevalence of esophageal motility disorders. |
| Dekel | 2004 | Not randomised, not controlled trial | PPI trial only 14 patients included (only GERD positive treated) |
| Deng | 2009 | cross-sectional study | No NCCP. Combination between cardiac ischemia and esophageal spasms |
| De Vries | 2006 | cross-sectional study | Mixed patient sample with cardiac and non-cardiac chest pain |
| Dickman | 2007 | cohort, prospective | No diagnostic study. Prevalence of GI findings in NCCP vs. patients with GERD |
| Disla | 1994 | cohort, prospective | No diagnostic study, prevalence |
| Domanovits | 2002 | cross-sectional study | Rule out cardiovascular disease. No diagnostic study for NCCP |
| Ellis | 1992 | cohort, prospective | No diagnostic study. Treatment outcome in patients with esophageal spasm |
| Elloway | 1992 | cross-sectional study | provocative radionuclide esophagealNo comparison to reference test, radionuclide esophageal transit (P-RET) investigation, small sample (n = 30) |
| Elloway | 1992 | cross-sectional study | Same study under different title |
| Erhardt | 2002 | Guideline | Task force on the management of chest pain |
| Esayag | 2008 | retrospective review | Pleuritic chest pain. No reference test, description of presentation and outcome |
| Esler | 2001 | randomized clinical trial | Dissertation, same as following. |
| Esler | 2003 | randomized clinical trial | Treatment intervention in NCCP. CBT in NCCP seems to reduce chest pain episodes |
| Fass | 1999 | cohort, prospective | No diagnostic study. Treatment outcome study |
| Fleischmann | 1997 | cross-sectional study | No NCCP. Echokardiographic findings in acute chest pain and health status |
| Fletcher | 2011 | cohort, prospective | Sample size: 8 patients with NCCP |
| Fornari | 2008 | cohort, retrospective | No NCCP. Only nutcracker esophagus investigated |
| Fournier | 1993 | cross-sectional study | No NCCP. Ergovine test during coronary angiogram and induction of coronary spasm |
| Fournier | 1993 | cross-sectional study | Same study under different titles |
| Foldes | 2011 | cross-sectional study | No comparison of test with reference test. Prevalence of panic disorders |
| Frobert | 1996 | cross-sectional study | No diagnostic study. Comparison of characteristics between NCCP with positive treadmill test compared to negative treadmill test. |
| Gentile | 2003 | cross-sectional study | Patients with pneumococcal pneumonia. No reference test, description of presentation, microbiological findings and mortality |
| Gignoux | 1993 | experimental | No diagnostic study, experimental study |
| Goehler | 2011 | experimental | Simulation model of CT scan |
| Goodacre | 2004 | randomized clinical trial | No diagnostic study. Comparison of treatments |
| Gustafsson | 1997 | non-randomised controlled trial | Sample size: intravenous edrophonium chloride test in 16 patients |
| Ha | 1998 | cross-sectional study | No only NCCP. Patients with suspected coronary artery spasm. Ergonovine provocation test and scintigrafic findings. Small sample (n = 26) |
| Hamm | 2011 | Guideline | ESC Guidelines |
| Herbella | 2009 | cross-sectional study | No NCCP. Presentation of GERD patients |
| Hess | 2008 | validation | Diagnostic accuracy to exclude coronary artery disease |
| Hillis | 2003 | observational | Correlation of predictors and long term outcome. No diagnostic study |
| Hick | 1992 | cohort, retrospective | No diagnostic study. Comparison of characteristics |
| Hirano | 2001 | cross-sectional study | No NCCP. Coronary artery spasm |
| Ho | 2001 | cross-sectional study | No diagnostic study. Difference between cardiovascular disease and non-cardiovascular disease |
| Hobson | 2006 | experimental | Experimental for pain threshold. |
| Hobson | 2006 | experimental | Same study under different titels |
| Howarth | 2003 | cohort, prospective | Ischemic heart disease and GERD |
| Hu | 2000 | experimental | Experimental trial in volunteers |
| Hughes | 2007 | cohort, retrospective | No diagnostic study. Risk factors for Reflux or NCCP |
| Hung | 2010 | review article | Review article about atypical chest pain |
| Ilgen | 2011 | validation | Diagnostic accuracy to exclude coronary artery disease |
| Jacobs | 2007 | Guideline | executive summary of management patients with ischemic heart disease |
| Jerlock | 2005 | qualitative study | No diagnostic study. Qualitative study |
| Johnston | 1993 | cohort, retrospective | No diagnostic study, prevalence |
| Jones | 1999 | cross-sectional study | Pleuritic chest pain. Review article |
| Kahrilas | 2011 | systematic review | Systematic Review PPI Trial in NCCP, reference publication for included studies |
| Kao | 1993 | cross-sectional study | No diagnostic study, prevalence |
| Karamanolis | 2008 | experimental | Healthy volunteers |
| Karlson | 1994 | observational | No diagnostic study. Prognosis and outcome after discharge for ER |
| Ke | 1993 | cohort, prospective | No diagnostic study, prevalence of GERD in NCCP |
| Keefe | 2011 | randomised clinical trial | No diagnostic study. Coping skills training, sertraline, placebo |
| Keogh | 2004 | cross-sectional study | No diagnostic study. Presence of various psychological factors in the ER in cardiac vs. NCCP on cardiac chest pain |
| Kisley | 1997 | cohort, prospective | No diagnostic study. Prognosis after discharge after first admission with acute chest pain |
| Klingerman | 2011 | cross-sectional study | Rule out cardiovascular disease. No diagnostic study for NCCP |
| Klopocka | 2005 | cohort, prospective | No diagnostic study. Only 24 patients with NCCP |
| Klopocka | 2005 | cohort, prospective | Same study under different titles |
| Koop | 2005 | journal article | GERD. No diagnostic study in NCCP |
| Kumarathurai | 2008 | cohort, prospective | No diagnostic study. |
| Kushner | 1992 | cross-sectional study | small sample: n = 27. Presence of panic disorders in relatives. |
| Lacy | 2009 | cross-sectional study | Prevalence study |
| Lam | 1994 | cohort, prospective | No diagnostic procedure. Only patients included that chest pain was reproduced during the investigation |
| Lanzarini | 1994 | cross-sectional study | Description of findings in dobutamine stress echocardiography in patients with positive exercise stress test and negative coronar angiography including ergonovine stress test. |
| Lauenbjerg | 1997 | observational | No diagnostic study. Long term prognosis in patients with NCCP of various etiologies |
| Lee | 2011 | randomised clinical trial | Conference proceeding. No diagnostic study |
| Lee | 2005 | cross-sectional study | Prevalence study |
| Lehtola | 2010 | randomised, controlled trial | Treatment outcome (manipulation, acupuncture vs. placebo. No diagnostic study |
| Lessard | 2012 | | Patients with NCCP with Panic disorders. Two different interventions, no diagnostic study |
| Lien | 2011 | cohort, prospective | NCCP not investigated |
| Lin | 2004 | cross-sectional study | No NCCP. GERD symptoms and underlying conditions. Differences between women and men |
| Liu | 2006 | cross-sectional study | No NCCP patients. Correlation analysis between psychological factors and findings |
| Lopez Gaston | 1994 | cross-sectional study | Only esophageal pain investigated not NCCP |
| Lopez Gaston | 1994 | cross-sectional study | Same study under different titles |
| Lopez Gaston | 1994 | cross-sectional study | Same study under different titles |
| Loten | 2009 | observational | No diagnostic study. Adverse outcome / prognosis of mixed patient population |
| Lyer | 2009 | retrospective review | Spontaneous pneumomediastinum. Presentation and findings. No diagnostic study |
| MacPherson | 2007 | cross-sectional study | No diagnostic study. Survey of patients after ER diagnosis NCCP about interest in acupuncture |
| Maev | 2007 | randomised clinical trial | Conference proceeding |
| Maev | 2007 | randomised clinical trial | Same study under different titles |
| Makk | 2000 | experimental | Experimental study. No diagnostic study. Comparison of acid infusion and cardiac vs. non-cardiac chest pain. Small sample |
| Manchikanti | 2003 | observational | No NCCP. Medial branch blocks for musculoskeletal pain |
| Manterola | 2004 | cross-sectional study | No diagnostic study. Clinical presentation of patients with NCCP |
| Martina | 1997 | cross-sectional study | All patients presenting in primary care. NCCP not as subgroup investigated |
| Matthews | 2005 | Meta-analysis | Meta-analysis for PPI-Trial |
| Mayou | 1994 | cohort, prospective | No diagnostic study. Comparison of NCCP vs. IHD patients |
| Mayou | 2002 | cohort, prospective | No diagnostic study. One year follow-up in comparison to cardiac chest pain. Comparison of costs to the CVD patients |
| Mearin | 1998 | cohort study, prospective | No diagnostic study. Change of habits during manometry |
| Mehta | 1995 | experimental | No reference test as “true positive” defined. |
| Mendelson | 1997 | cohort, prospective | Reference test are cancer patients. Comparison of Szintigraphy for the diagnosis of costochondritis |
| Mitchell | 2006 | cross-sectional study | Prevalence of risk factors and pretest probability |
| Miniati | 1999 | cross-sectional study | no NCCP. Pulmonary embolism |
| Miniati | 2001 | cross-sectional study | no NCCP. Pulmonary embolism |
| Miniati | 2003 | cross-sectional study | no NCCP. Prediction model for pulmonary embolism |
| Mujica | 2001 | cohort, prospective | No diagnostic study in patients. Healthy volunteers |
| Mulero | 1999 | cross-sectional study | Small sample (n = 24). No reference test. Descriptive findings in SPECT |
| Munk | 2008 | cohort, prospective | No diagnostic study. Risk of death in patients with unexplained chest pain |
| Nanbu | 1997 | cross-sectional study | Focus on difference between IHD and NCCP patients. Valdity of the medical interview for patients with NCCP |
| Nasr | 2010 | experimental | Experimental study. |
| Nasr | 2010 | experimental | Same study under different titels |
| Nellemann | 2000 | experimental | Small sample (n = 5 with chest pain) |
| Nevitt | 1999 | secondary analysis of an RCT | No NCCP. Vertebral fracture |
| Nikolic | 2010 | cross-sectional study | No diagnostic study. Comparison of NCCP to IHD patients |
| Nilsson | 2003 | cross-sectional study | Prevalence of Diagnosis of IHD in primary care. |
| Okada | 1993 | cross-sectional study | No NCCP. Provocation of myocardial ischemia by hyperventilation |
| Oliver | 1999 | cross-sectional study | CT in acute non-cardiac chest pain. No reference. Description of diagnoses found. |
| Pandak | 2002 | cross-sectional study | duplicate of the study included in the analysis |
| Panju | 1996 | observational | No diagnostic study. Patients prognosis after discharge |
| Paterson | 1993 | cohort, prospective | exclude, small sample |
| Paterson | 1995 | cross-sectional study | No diagnostic study. Description of finding in balloon distention NCCP in comparison to other pain patients |
| Paterson | 1996 | cross-sectional study | Not enough information to populate a two by two table. Small sample (n = 23) |
| Porter-Moffitt | 2006 | cross-sectional study | Small sample (Chest pain n = 34). Comparison of findings to other pain diagnosis. |
| Rasmussen | 2009 | cohort, prospective | No NCCP. Complex regional pain syndrome |
| Robertson | 2008 | cross-sectional study | Comparison of psychological morbidity in cardiac vs. Non-cardiac chest pain |
| Rosano | 1996 | randomised clinical trial | No diagnostic study. Treatment of 17-beta-estradiol patches compared to placebo on NCCP in postmenopausal women |
| Ratnaike | 1993 | retrospective review | No diagnostic study. Audit for IHD |
| Rate | 1999 | experimental | healthy volunteers |
| Rencoret | 2006 | cross-sectional study | No diagnostic study. Prevalence of esophageal disorders in patients with NCCP compared to other GI diseases |
| Repasky | 2005 | validation | ED chest pain pathway |
| Rokkas | 1992 | cross-sectional study | Not enough information to populate the two by two table |
| Rose | 1994 | cohort, prospective | No diagnostic study. Does esophageal testing prevent persistence of symptoms? No control group |
| Rose | 1994 | cohort, prospective | Same study under different titles |
| Rosengren | 2008 | Editorial | Editorial |
| Rousset | 2011 | retrospective review | No NCCP. Catammenial pneumothorax and endometriosis-related pneumothorax |
| Ruigomez | 2004 | cohort study | No diagnostic study. Description of risk factors, incidence and comorbidities |
| Sakata | 1996 | cross-sectional study | No reference test. Description of homeostasis and fibrinolysis in patients with coronary artery spasm. Not sure only NCCP patients |
| Sakamoto | 2011 | cross-sectional study | Acute chest pain, rule out aortic dissection or pulmonary embolism |
| Salles | 2011 | cohort, retrospective | No diagnostic study: SAPHO syndrome, clinical characteristics. |
| Sanchis | 2008 | cross-sectional study | clinical risk profile of patients with acute chest pain without ST-segment deviation or troponin elevation |
| Scarinci | 1994 | cohort, prospective | No NCCP. Women with GERD clinical presentation |
| Schima | 1992 | cohort, prospective | Small sample (n = 4 NCCP) |
| Schima | 1992 | cohort, prospective | Same study under different titles |
| Schmidt | 2002 | cross-sectional study | No NCCP. General pain patients |
| Schmulson | 2004 | review article | Review article about atypical chest pain |
| Shahid | 2005 | cross-sectional study | No diagnostic study. Prensentation of young adults with chest pain |
| Shapiro | 2006 | | No NCCP patients. Functional heart burn (pH Man normal) vs. NERD (ph manometry pathologic) incl. psychometric profile). |
| Sharma | 2010 | experimental | healthy volunteers |
| Shelby | 2009 | randomized clinical trial | Same sample as 210 and 217. Description of psychological factors at baseline. |
| Sigurdsson | 2009 | retrospective review | Retrospective analysis of lung biopsy. No NCCP group |
| Singh | 1993 | retrospective review | duplicate of the included study |
| Smith | 2000 | retrospective review | Feasibility study based on records in a chiropractic clinic. |
| Smout | 1992 | experimental | experimental. Small sample (n = 10) |
| Sobralske | 2005 | review article | Review article about atypical chest pain |
| Spencer | 2006 | observational | No NCCP. GI patients long term outcome |
| Sporer | 2007 | cross-sectional study | Rule out cardiovascular disease. No diagnostic study for NCCP |
| Stahl | 1994 | cohort, prospective | Small sample (n = 13 NCCP patients) |
| Steurer | 2010 | Metaanalysis | clinical value of diagnostic instruments to rule out IHD |
| Stochkendahl | 2008 | randomised clinical trial | Study protocol |
| Stochkendahl | 2012 | randomised, controlled trial | No diagnostic study. Treatment outcome |
| Stochkendahl | 2012 | randomised, controlled trial | No diagnostic study. Same study as previous. Treatment outcome 1 year follow-up |
| Stollman | 1997 | cross-sectional study | Small sample (n = 14 patients) |
| Taylor | 2002 | cross-sectional study | Rule out strategy cardiovascular patients. No diagnostic study in NCCP |
| Taniguchi | 2009 | cross-sectional study | Chest pain in asthma. Treatment response to bronchodilatators |
| Tew | 1995 | cross-sectional study | No diagnostic study. Outcome cardiovascular patients |
| Tougas | 2001 | experimental | Experimental. Autonomic reaction to acid infusion in NCCP patients (n = 28) compared to controls |
| Triadafilopoulos | 1997 | cohort, prospective | GERD patients. Description of spectrum of patients. Only a few with NCCP |
| Tutuian | 2006 | cross-sectional study | Not enough information to populate a two by two table in NCCP patients with esophageal spasm |
| Valdovinos | 2004 | experimental | No reference test. pH Bravo- capsule. Safety, efficacy and experience in 11 patients |
| Van Kleef | 1995 | observational | No diagnostic study. Intervention success comparison after radiofrequency lesion of the dorsal root ganglion |
| Van Peski-Oosterbaan | 1998 | cross-sectional study | Survey about how people are interested in psychological treatment after discharge after cardiac unit admission. Mixed patients sample. |
| van Ravensteijn | 2012 | systematic review | Diagnostic test efficacy in various pain patients |
| Varia | 2000 | randomised, controlled trial | No diagnostic study. Comparison efficacy Sertraline vs. Placebo. |
| Vent | 2010 | journal article | dysphagia cause of chest pain |
| Verdon | 2010 | observational | Chest pain early diagnostic guess accuracy in GP’s |
| Vermeltfoort | 2009 | cross-sectional study | Mixed patient sample with cardiac and non-cardiac chest pain |
| Volpicelli | 2008 | cohort, prospective | Pleural sonography for the diagnosis of pulmonary embolism |
| Wang | 2011 | cross-sectional study | Conference proceeding |
| Watkins | 2011 | journal article | Diagnosis and management of community-acquired pneumonia |
| Weiner | 2006 | journal article | Cardiac markers in low-risk patients. No study |
| Weingarten | 1993 | cross-sectional study | No diagnostic study for NCCP. Reduction of length of stay by complying the guidelines |
| White | 2011 | cross-sectional study | no diagnostic study. Prevalence |
| Wong | 2002 | cohort, prospective | no comparison to a reference test. Descriptive information only. |
| Wulsin | 2002 | randomised clinical trial | no diagnostic study. Treatment of paroxetine vs. usual care |
| Yelland | 2010 | review article | Review article about atypical chest pain |
| Yu | 1997 | cross-sectional study | Not enough information to populate a two by two table for symptom index and the presence of GERD |
| Zalar | 1995 | cross-sectional study | Conference proceeding |
| Zarauza | 2003 | observational | No diagnostic study. Follow-up after discharge |
| Zheng | 2008 | cross-sectional study | Small sample (n = 27) |
| Zheng | 2008 | cross-sectional study | Same study under different title |
Summary of the Scottish Intercollegiate Guidelines Network (SIGN) quality assessment [19]
| Dickman [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | N/A | ++ |
| Bautista [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | N/A | ++ |
| Fass [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | ++ |
| Pandak [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | PA | PA | + |
| Kim [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | PA | PA | ++ |
| Xia [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | ++ |
| Kushinir [ | WC | WC | AA | PA | WC | WC | WC | WC | WC | NA | NA | N/A | PA | + |
| Lacima [ | WC | PA | WC | WC | WC | WC | WC | WC | WC | NA | NA | WC | WC | + |
| Cooke [ | WC | AA | WC | WC | WC | WC | WC | WC | WC | NA | NA | WC | WC | + |
| Bovero [ | WC | PA | WC | WC | WC | WC | WC | WC | WC | NA | NA | WC | WC | + |
| Romand [ | WC | AA | WC | WC | WC | WC | WC | WC | WC | NA | NA | WC | WC | + |
| Abrahao [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | NA | NA | WC | WC | ++ |
| Ho [ | WC | PA | WC | WC | WC | WC | WC | WC | WC | NA | NA | PA | WC | + |
| Kim [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | NA | NA | WC | WC | ++ |
| Hong [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | NA | NA | WC | WC | ++ |
| Netzer [ | WC | AA | WC | WC | WC | WC | WC | PA | WC | NA | NA | WC | WC | + |
| Mousavi [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | NA | NA | WC | WC | ++ |
| Singh [ | WC | PA | WC | WC | WC | WC | WC | AA | WC | NA | NA | WC | WC | + |
| Lam [ | WC | PA | WC | WC | WC | WC | WC | WC | WC | NA | NA | WC | WC | + |
| Achem [ | WC | WC | WC | WC | WC | WC | WC | AA | WC | NA | NA | WC | WC | + |
| Demiryoguran [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | ++ |
| Foldes-Busque [ | WC | WC | WC | WC | WC | WC | WC | WC | AA | WC | NA | WC | N/A | ++ |
| Kujipers [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | NA | NA | WC | WC | ++ |
| Katerndahl [ | WC | AA | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | ++ |
| Fleet [ | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | ++ |
| Stochkendahl [ | WC | WC | WC | NA | WC | WC | PA | WC | WC | NA | NA | WC | WC | + |
| Manchikanti [ | WC | WC | WC | WC | PA | PA | WC | WC | WC | WC | PA | PA | WC | + |
| Bosner [ | WC | WC | WC | WC | WC | WC | WC | AA | WC | WC | AA | WC | WC | ++ |
1.1: spectrum of patients is representative of patients who will receive the test; 1.2: selection criteria described; 1.3: reference standard is likely to classify the condition correctly; 1.4: period between reference standard and index test short enough; 1.5: whole sample received verification of diagnosis; 1.6: patients receive same reference test regardless of index test results; 1.7: reference standard independent of index test; 1.8: execution of index test described in detail; 1.9: reference standard described in detail; 1.10: index test interpreted without knowledge of result of reference test; 1.11: reference standard results interpreted without knowledge of result index test; 1.12: uninterpretable or intermediate results are reported; 1.13: explanation is provided for withdrawals; 2.1: reliability of the conclusion of the study. Risk of bias (2.1) is as follows. (++), high quality: most of the criteria have been fulfilled. If not fulfilled, the conclusions of the study are very unlikely to alter. (+), moderate quality: some criteria fulfilled. Criteria not adequately described are unlikely to alter the conclusions. (−), low quality: few or no criteria fulfilled. The conclusions are likely to alter.
AA adequately addressed, N/A not applicable, NA not addressed, NR not reported, PA poorly addressed, WC well covered.
Summary of all tests evaluated
| Symptoms | |||||||||||||||
| Kim | NCCP with atypical GERD symptoms | Endoscopy (LA classification) and/or 24 h pH-metry (>4%, pH <4 | 3 | 20 | 5 | 6 | 0.38 | 0.23 | 0.13 | 0.55 | 0.49 | 2.71 | 24 | 13 | 45 |
| Kim | NCCP with typical GERD symptoms | Endoscopy (LA classification) and/or 24 h pH-metry (>4%, pH <4 | 11 | 2 | 5 | 6 | 0.69 | 0.75 | 0.85 | 0.55 | 2.75 | 0.42 | 67 | 85 | 45 |
| Mousavi | NCCP with typical GERD symptoms | GERD if two tests positive: endoscopy (Hentzel-Dent), Bernstein test, omeprazole trial | 11 | 5 | 24 | 38 | 0.31 | 0.88 | 0.69 | 0.61 | 2.70 | 0.78 | 45 | 69 | 39 |
| Mousavi | NCCP relieved by antacid | GERD if two tests positive: endoscopy (Hentzel-Dent), Bernstein test, omeprazole trial | 15 | 36 | 20 | 7 | 0.43 | 0.16 | 0.68 | 0.64 | 0.51 | 3.51 | 45 | 29 | 74 |
| Mousavi | NCCP and heartburn in history | GERD if two tests positive: endoscopy (Hentzel-Dent), Bernstein test, omeprazole trial | 14 | 8 | 21 | 35 | 0.40 | 0.81 | 0.64 | 0.63 | 2.15 | 0.74 | 45 | 64 | 38 |
| Mousavi | NCCP and regurgitation in history | GERD if two tests positive: endoscopy (Hentzel-Dent), Bernstein test, omeprazole trial | 17 | 7 | 18 | 36 | 0.49 | 0.84 | 0.71 | 0.67 | 2.98 | 0.61 | 45 | 71 | 33 |
| Hong | NCCP | Manometry (Specler 2001 criteria) and/or 24 h pH-metry (>4% pH <4) | 72 | 114 | 128 | 148 | 0.36 | 0.56 | 0.39 | 0.54 | 0.83 | 1.13 | 43 | 39 | 46 |
| Hong | Control: dysphagia | Manometry (Specler 2001 criteria) and/or 24 h pH-metry (>4% pH <4) | 27 | 26 | 181 | 228 | 0.13 | 0.90 | 0.51 | 0.56 | 1.27 | 0.97 | 45 | 51 | 44 |
| Hong | Control: GERD-typical symptoms | Manometry (Specler 2001 criteria) and/or 24 h pH-metry (>4% pH <4) | 53 | 53 | 151 | 205 | 0.26 | 0.79 | 0.50 | 0.58 | 1.26 | 0.93 | 44 | 50 | 42 |
| Hong | Dysphagia | Manometry | 16 | 37 | 84 | 325 | 0.16 | 0.90 | 0.30 | 0.80 | 1.57 | 0.94 | 22 | 30 | 21 |
| Hong | Dysphagia | 24 h pH-metry | 4 | 49 | 63 | 346 | 0.06 | 0.88 | 0.08 | 0.85 | 0.48 | 1.07 | 15 | 8 | 15 |
| Hong | Dysphagia | Manometry and 24 h pH-metry | 7 | 46 | 23 | 386 | 0.23 | 0.89 | 0.13 | 0.94 | 2.19 | 0.86 | 7 | 13 | 6 |
| Hong | NCCP | Manometry | 34 | 152 | 63 | 213 | 0.35 | 0.58 | 0.18 | 0.77 | 0.84 | 1.11 | 21 | 18 | 23 |
| Hong | NCCP | 24 h pH-metry | 29 | 157 | 43 | 233 | 0.40 | 0.60 | 0.16 | 0.60 | 1.00 | 1.00 | 16 | 16 | 16 |
| Hong | NCCP | Manometry and 24 h pH-metry | 9 | 177 | 22 | 254 | 0.29 | 0.59 | 0.05 | 0.92 | 0.71 | 1.20 | 7 | 5 | 8 |
| Hong | GERD-typical symptoms | Manometry | 19 | 87 | 81 | 275 | 0.19 | 0.76 | 0.18 | 0.77 | 0.79 | 1.07 | 22 | 18 | 23 |
| Hong | GERD-typical symptoms | 24 h pH-metry | 23 | 83 | 49 | 307 | 0.32 | 0.79 | 0.22 | 0.86 | 1.50 | 0.86 | 16 | 22 | 14 |
| Hong | GERD-typical symptoms | Manometry and 24 h pH-metry | 11 | 95 | 20 | 336 | 0.35 | 0.78 | 0.10 | 0.94 | 1.61 | 0.83 | 7 | 10 | 6 |
| Netzer | NCCP | Manometry and/or 24 h pH-metry (>10.5% pH <4) | 31 | 14 | 223 | 35 | 0.12 | 0.71 | 0.69 | 0.14 | 0.43 | 1.23 | 84 | 69 | 86 |
| Netzer | Control: GERD-typical symptoms | Manometry and/or 24 h pH-metry (>10.5% pH <4) | 127 | 16 | 127 | 33 | 0.50 | 0.67 | 0.89 | 0.21 | 1.53 | 0.74 | 84 | 89 | 79 |
| Netzer | Control: dysphagia | Manometry and/or 24 h pH-metry (>10.5% pH <4) | 48 | 8 | 206 | 41 | 0.19 | 0.84 | 0.86 | 0.17 | 1.16 | 0.97 | 84 | 86 | 83 |
| Netzer | GERD-typical symptoms | 24 h pH-metry | 115 | 28 | 49 | 111 | 0.70 | 0.80 | 0.80 | 0.69 | 3.48 | 0.37 | 54 | 80 | 31 |
| Netzer | Dysphagia | 24 h pH-metry | 6 | 50 | 158 | 89 | 0.04 | 0.64 | 0.11 | 0.36 | 0.10 | 1.50 | 54 | 11 | 64 |
| Netzer | NCCP | 24 h pH-metry | 24 | 21 | 140 | 118 | 0.15 | 0.85 | 0.53 | 0.46 | 0.97 | 1.01 | 54 | 53 | 54 |
| PPI trial | |||||||||||||||
| Dickman | Rabeprazole 20 mg twice a day for 1 week SIS ≥50% | Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry (>4.2% pH <4) | 12 | 2 | 4 | 17 | 0.75 | 0.89 | 0.86 | 0.81 | 7.13 | 0.28 | 46 | 86 | 19 |
| Dickman | Placebo for 1 week | Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry (>4.2% pH <4) | 3 | 4 | 13 | 15 | 0.19 | 0.79 | 0.43 | 0.54 | 0.89 | 1.03 | 46 | 43 | 46 |
| Bautista | Lansoprazole 60 mg AM, 30 mg PM for 1 week SIS ≥50% | Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry (>4.2% pH <4) | 14 | 2 | 4 | 20 | 0.78 | 0.91 | 0.875 | 0.833 | 8.56 | 0.24 | 45 | 88 | 17 |
| Bautista | Lansoprazole 60 mg AM, 30 mg PM for 1 week SIS ≥65% | Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry (>4.2% pH <4) | 15 | 1 | 3 | 21 | 0.83 | 0.95 | 0.93 | 0.88 | 18.33 | 0.17 | 45 | 94 | 13 |
| Bautista | Placebo for 1 week | Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry (>4.2% pH <4) | 4 | 8 | 14 | 14 | 0.22 | 0.64 | 0.33 | 0.50 | 0.61 | 1.22 | 45 | 33 | 50 |
| Fass | Omeprazole 40 mg AM, 20 mg PM for 1 week SIS ≥50% | Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry (>4.2% pH <4) | 18 | 2 | 5 | 12 | 0.78 | 0.86 | 0.90 | 0.71 | 5.48 | 0.25 | 62 | 90 | 29 |
| Fass | Placebo for 1 week | Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry (>4.2% pH <4) | 5 | 1 | 18 | 13 | 0.22 | 0.93 | 0.83 | 0.42 | 3.04 | 0.84 | 62 | 83 | 58 |
| Pandak | Omeprazole 40 mg twice a day for 2 weeks SIS ≥50% | Endoscopy and/or 24 h pH-metry (>4.2% pH <4) | 18 | 6 | 2 | 12 | 0.90 | 0.67 | 0.75 | 0.86 | 2.70 | 0.15 | 53 | 75 | 14 |
| Pandak | Placebo for 2 weeks SIS ≥50% | Endoscopy and/or 24 h pH-metry (>4.2% pH <4) | 1 | 3 | 19 | 15 | 0.05 | 0.83 | 0.25 | 0.44 | 0.30 | 1.14 | 53 | 25 | 56 |
| Kim | NCCP GERD-related (TP) vs NCCP non-GERD-related (TN): rabeprazole for 1 week SIS ≥50% | Endoscopy (LA classification) and/or 24 h pH-metry (>4.0 pH <4) | 8 | 6 | 8 | 20 | 0.50 | 0.77 | 0.57 | 0.71 | 2.17 | 0.65 | 38 | 57 | 29 |
| Kim | NCCP GERD-related (TP) vs NCCP non-GERD-related (TN): rabeprazole for 2 weeks SIS ≥50% | Endoscopy (LA classification) and/or 24 h pH-metry (>4.0 pH <4) | 13 | 7 | 3 | 19 | 0.81 | 0.73 | 0.65 | 0.86 | 3.02 | 0.26 | 38 | 65 | 14 |
| Xia | Lansoprazole 30 mg once a day for 4 weeks SIS ≥50% | 24 h pH-metry (De Meester pH <4, 7.5 s) | 11 | 8 | 1 | 16 | 0.92 | 0.67 | 0.58 | 0.94 | 2.75 | 0.13 | 33 | 58 | 6 |
| Xia | Placebo for 4 weeks SIS ≥50% | 24 h pH-metry (De Meester pH <4, 7.5 s) | 4 | 7 | 8 | 13 | 0.33 | 0.65 | 0.36 | 0.62 | 0.95 | 1.03 | 38 | 36 | 38 |
| Kushnir | High-degree response on PPI (not specified) | 24 pH-metry (≥4%, pH <4) | 40 | 18 | 12 | 28 | 0.77 | 0.61 | 0.69 | 0.70 | 1.97 | 0.38 | 53 | 69 | 30 |
| Kushnir | High-degree response on PPI | Positive Ghillibert probability estimate (GPE) | 21 | 37 | 5 | 35 | 0.81 | 0.49 | 0.36 | 0.88 | 1.57 | 0.40 | 27 | 36 | 12 |
| Kushnir | High-degree response on PPI | Association of chest pain with pH <4 in reference standard: SI ≥50% | 19 | 39 | 6 | 34 | 0.76 | 0.47 | 0.33 | 0.85 | 1.42 | 0.52 | 26 | 33 | 15 |
| Kushnir | High-degree response on PPI | 24 h pH-metry and positive GPE | 15 | 43 | 2 | 38 | 0.88 | 0.47 | 0.26 | 0.95 | 1.66 | 0.25 | 17 | 26 | 5 |
| Kushnir | High-degree response on PPI | 24 h pH-metry and SI ≥50% | 16 | 42 | 2 | 38 | 0.89 | 0.48 | 0.28 | 0.95 | 1.69 | 0.23 | 18 | 28 | 5 |
| Kushnir | High-degree response on PPI | 24 h pH-metry and SI ≥50% and positive GPE | 14 | 44 | 1 | 39 | 0.93 | 0.47 | 0.24 | 0.98 | 1.76 | 0.14 | 15 | 24 | 2 |
| Symptom index | |||||||||||||||
| Singh | Association of chest pain with pH <4 in reference standard: SI ≥50% | Endoscopy and/or 24 h pH-metry (De Meester >5.5% pH <4) | 19 | 38 | 15 | 81 | 0.56 | 0.68 | 0.33 | 0.84 | 1.75 | 0.65 | 22 | 33 | 16 |
| Singh | Association of chest pain with pH <4 in reference standard: SI ≥25% | Endoscopy and/or 24 h pH-metry (De Meester >5.5% pH <4) | 23 | 59 | 11 | 60 | 0.68 | 0.50 | 0.28 | 0.85 | 1.36 | 0.64 | 22 | 28 | 15 |
| Singh | Association of chest pain with pH <4 in reference standard: SI ≥75% | Endoscopy and/or 24 h pH-metry (De Meester >5.5% pH <4) | 8 | 5 | 26 | 114 | 0.24 | 0.96 | 0.62 | 0.81 | 5.60 | 0.80 | 22 | 62 | 19 |
| Singh | Association of heartburn with pH <4 in reference standard: Symptom Index (SI) ≥50% | Endoscopy and/or 24 h pH-metry (De Meester >5.5% pH <4) | 40 | 32 | 3 | 78 | 0.93 | 0.71 | 0.56 | 0.96 | 3.20 | 0.10 | 28 | 56 | 4 |
| Singh | Association of heartburn with pH <4 in reference standard: SI ≥25% | Endoscopy and/or 24 h pH-metry (De Meester >5.5% pH <4) | 41 | 40 | 2 | 70 | 0.95 | 0.64 | 0.51 | 0.97 | 2.62 | 0.07 | 28 | 51 | 3 |
| Singh | Association of heartburn with pH <4 in reference standard: SI ≥75% | Endoscopy and/or 24 h pH-metry (De Meester >5.5% pH <4) | 25 | 25 | 9 | 94 | 0.74 | 0.79 | 0.50 | 0.91 | 3.50 | 0.34 | 28 | 58 | 12 |
| Ho | Association of chest pain with pH <4 in reference standard: SI >50% | 24 h pH-metry (>4% pH <4, 4 s) | 3 | 9 | 11 | 38 | 0.21 | 0.81 | 0.25 | 0.78 | 1.12 | 0.97 | 23 | 25 | 22 |
| Lam | Association of chest pain with pH <4 in reference standard: SI ≥75% | 24 h pH-metry (execution in acute stage) | 13 | 0 | 15 | 13 | 0.46 | 1.00 | 1.00 | 0.48 | 13.03 | 0.54 | 68 | 97 | 54 |
| Others | |||||||||||||||
| Lacima | 24 h-manometry (pH <4) | Manometry during hospital stay | 18 | 24 | 18 | 30 | 0.50 | 0.56 | 0.43 | 0.56 | 1.13 | 0.90 | 40 | 43 | 38 |
| Provocation test | |||||||||||||||
| Cooke | NCCP during exertional pH-metry | 24 h pH-metry (5.5% pH <4 for 10 s) | 4 | 0 | 15 | 31 | 0.21 | 1.00 | 1.00 | 0.67 | 14.40 | 0.79 | 38 | 90 | 33 |
| Cooke | Control group: CVD with angina: exertional pH-metry | 24 h pH-metry (5.5% pH <4 for 10 s) | 1 | 1 | 2 | 12 | 0.33 | 0.92 | 0.50 | 0.86 | 4.33 | 0.72 | 19 | 50 | 14 |
| Bovero | NCCP with normal ECG during exertional pH-metry | 24 h pH-metry (De Meester criteria: >4.5% pH <4)) | 17 | 1 | 29 | 20 | 0.37 | 0.95 | 0.94 | 0.41 | 7.76 | 0.66 | 69 | 94 | 59 |
| Bovero | NCCP at rest: NCCP with normal ECG during exertional pH-metry | 24 h pH-metry (De Meester criteria: >4.5% pH <4)) | 11 | 1 | 23 | 11 | 0.32 | 0.92 | 0.92 | 0.32 | 3.88 | 0.74 | 74 | 92 | 68 |
| Bovero | NCCP exertion/mixed: NCCP with normal ECG during exertional pH-metry | 24 h pH-metry (De Meester criteria: >4.5% pH <4)) | 6 | 0 | 6 | 9 | 0.50 | 1.00 | 1.00 | 0.60 | 10.00 | 0.50 | 57 | 93 | 40 |
| Bovero | 24 h pH-metry (De Meester criteria: >4.5% pH <4)) | NCCP with normal ECG during exertional pH-metry | 17 | 29 | 1 | 20 | 0.94 | 0.41 | 0.37 | 0.95 | 1.60 | 0.14 | 27 | 37 | 5 |
| Bovero | 24 h pH-metry (De Meester criteria: >4.5% pH <4)) | NCCP at rest: NCCP with normal ECG during exertional pH-metry | 11 | 23 | 1 | 11 | 0.92 | 0.32 | 0.32 | 0.92 | 1.36 | 0.26 | 26 | 32 | 8 |
| Romand | NCCP: pH <4 for 10 s during exertional pH-metry | 24 h pH-metry (De Meester criteria: >4.5% pH <4)) | 7 | 14 | 3 | 19 | 0.70 | 0.58 | 0.33 | 0.86 | 1.65 | 0.52 | 23 | 33 | 14 |
| Abrahao | NCCP reproducible during balloon distension | Endoscopy (Savary-Miller) and/or manometry and/or pH-metry (De Meester criteria: >4.5% pH <4 | 14 | 1 | 21 | 4 | 0.40 | 0.80 | 0.93 | 0.16 | 2.00 | 0.75 | 88 | 93 | 84 |
| Abrahao | NCCP reproducible during Tensilon test | Endoscopy (Savary-Miller) and/or manometry and/or pH-metry (De Meester criteria: >4.5% pH <4 | 6 | 2 | 29 | 3 | 0.17 | 0.60 | 0.75 | 0.09 | 0.43 | 1.38 | 88 | 75 | 91 |
| Abrahao | NCCP reproducible during Bernstein test | Endoscopy (Savary-Miller) and/or manometry and/or pH-metry (De Meester criteria: >4.5% pH <4 | 9 | 1 | 26 | 4 | 0.26 | 0.80 | 0.90 | 0.13 | 1.29 | 0.93 | 88 | 90 | 87 |
| Abrahao | Tensilon and Bernstein Test and balloon distension (+ if 1 test +) | Endoscopy (Savary-Miller) and/or manometry and/or pH-metry (De Meester criteria: >4.5% pH <4 | 20 | 3 | 15 | 2 | 0.57 | 0.40 | 0.87 | 0.12 | 0.95 | 1.07 | 88 | 87 | 88 |
| Abrahao | NCCP reproducible during Tensilon test | Endoscopy (Savary-Miller) and/or pH-metry (De Meester criteria: >4.5% pH <4 | 6 | 2 | 26 | 6 | 0.19 | 0.75 | 0.75 | 0.19 | 0.75 | 1.08 | 80 | 75 | 81 |
| Abrahao | NCCP reproducible during Bernstein test | Endoscopy (Savary-Miller) and/or pH-metry (De Meester criteria: >4.5% pH <4 | 8 | 2 | 24 | 6 | 0.25 | 0.75 | 0.80 | 0.20 | 1.00 | 1.00 | 80 | 80 | 80 |
| Abrahao | NCCP reproducible during balloon distension | Endoscopy (Savary-Miller) and/or pH-metry (De Meester criteria: >4.5% pH <4 | 13 | 2 | 19 | 6 | 0.41 | 0.75 | 0.87 | 0.24 | 1.63 | 0.79 | 80 | 87 | 76 |
| Abrahao | Tensilon and Bernstein Test and balloon distension (+ if 1 test +) | Endoscopy (Savary-Miller) and/or pH-metry (De Meester criteria: >4.5% pH <4 | 18 | 5 | 14 | 3 | 0.56 | 0.38 | 0.78 | 0.18 | 0.90 | 1.17 | 80 | 78 | 82 |
| Ho | NCCP reproducible during Bernstein test | Endoscopy | 4 | 7 | 3 | 56 | 0.57 | 0.89 | 0.36 | 0.95 | 5.14 | 0.48 | 10 | 36 | 5 |
| Eosinophilia | |||||||||||||||
| Achem | Current GERD symptoms | Esophageal biopsies | 10 | 26 | 14 | 121 | 0.42 | 0.82 | 0.28 | 0.90 | 2.36 | 0.71 | 14 | 28 | 10 |
| Achem | Male gender or current GERD symptoms | Esophageal biopsies | 18 | 69 | 6 | 78 | 0.75 | 0.53 | 0.21 | 0.93 | 1.60 | 0.47 | 14 | 21 | 7 |
| Achem | Male gender or any abnormal EoE endoscopic finding | Esophageal biopsies | 23 | 79 | 1 | 68 | 0.96 | 0.46 | 0.23 | 0.99 | 1.78 | 0.09 | 14 | 23 | 1 |
| Achem | Current GERD symptoms or any abnormal EoE endoscopic finding | Esophageal biopsies | 20 | 63 | 4 | 84 | 0.83 | 0.57 | 0.24 | 0.96 | 1.94 | 0.29 | 14 | 24 | 5 |
| Musculoskeletal | |||||||||||||||
| Stochkendahl | Biomechanical dysfunction | Standardized examination protocol | 112 | 120 | 0 | 70 | 1.00 | 0.37 | 0.48 | 1.00 | 1.58 | 0.00 | 37 | 48 | 0 |
| Stochkendahl | ≥3 of 5 overall palpation findings | Standardized examination protocol | 111 | 124 | 1 | 66 | 0.99 | 0.35 | 0.47 | 0.99 | 1.52 | 0.03 | 37 | 47 | 1 |
| Bosner | Chest wall symptom (CWS) score: localized muscle tension, stinging pain, pain reproducible by palpation, absence of cough, cut-off test negative 0 to 1 points | Interdisciplinary consensus: cardiologist, GP, research associate (based on reviewed baseline, follow-up data) | 506 | 318 | 59 | 329 | 0.90 | 0.51 | 0.66 | 0.82 | 1.82 | 0.20 | 47 | 61 | 15 |
| Bosner | CWS score: localized muscle tension, stinging pain, pain reproducible by palpation, absence of cough, cut-off test negative 0 to 2 points | Interdisciplinary consensus | 357 | 135 | 208 | 512 | 0.63 | 0.79 | 0.76 | 0.67 | 3.02 | 0.47 | 47 | 72 | 29 |
| Stochkendahl | Anterior chest wall tenderness | Standardized examination protocol | 110 | 134 | 2 | 56 | 0.98 | 0.29 | 0.45 | 0.97 | 1.39 | 0.06 | 37 | 45 | 3 |
| Stochkendahl | Angina pectoris (uncertain or negative) | Standardized examination protocol | 109 | 147 | 3 | 43 | 0.97 | 0.23 | 0.43 | 0.94 | 1.26 | 0.12 | 37 | 43 | 7 |
| Stochkendahl | Pain worse on movement of torso | Standardized examination protocol | 32 | 16 | 80 | 174 | 0.29 | 0.92 | 0.67 | 0.69 | 3.39 | 0.78 | 37 | 67 | 32 |
| Bosner | Pain worse with movement | Interdisciplinary consensus | 221 | 119 | 344 | 528 | 0.39 | 0.82 | 0.65 | 0.61 | 2.13 | 0.75 | 47 | 65 | 40 |
| Stochkendahl | Positive/possible belief in pain origin from muscle/joints | Standardized examination protocol | 108 | 156 | 4 | 34 | 0.96 | 0.18 | 0.41 | 0.90 | 1.17 | 0.20 | 37 | 41 | 11 |
| Stochkendahl | Pain relief on pain medication | Standardized examination protocol | 25 | 13 | 87 | 177 | 0.22 | 0.93 | 0.66 | 0.67 | 3.26 | 0.83 | 37 | 66 | 33 |
| Bosner | Pain reproducible by palpation | Interdisciplinary consensus | 351 | 193 | 214 | 454 | 0.62 | 0.70 | 0.68 | 0.64 | 2.08 | 0.54 | 47 | 65 | 32 |
| Stochkendahl | Paraspinal tenderness | Standardized examination protocol | 90 | 112 | 22 | 78 | 0.80 | 0.41 | 0.45 | 0.78 | 1.36 | 0.48 | 37 | 45 | 22 |
| Bosner | Localized muscle tension | Interdisciplinary consensus | 346 | 164 | 219 | 483 | 0.61 | 0.75 | 0.71 | 0.66 | 2.41 | 0.52 | 47 | 68 | 32 |
| Stochkendahl | Chest pain present now | Standardized examination protocol | 92 | 116 | 20 | 74 | 0.82 | 0.39 | 0.44 | 0.79 | 1.35 | 0.46 | 37 | 44 | 21 |
| Bosner | Pain now | Interdisciplinary consensus | 328 | 327 | 237 | 320 | 0.58 | 0.49 | 0.50 | 0.57 | 1.15 | 0.85 | 47 | 50 | 43 |
| Stochkendahl | Pain debut not during a meal | Standardized examination protocol | 109 | 168 | 3 | 22 | 0.97 | 0.12 | 0.39 | 0.88 | 1.10 | 0.23 | 37 | 39 | 12 |
| Stochkendahl | Sharp pain | Standardized examination protocol | 39 | 35 | 73 | 155 | 0.35 | 0.82 | 0.53 | 0.68 | 1.89 | 0.80 | 37 | 53 | 32 |
| Bosner | Stinging pain | Interdisciplinary consensus | 299 | 184 | 266 | 463 | 0.53 | 0.72 | 0.62 | 0.63 | 1.87 | 0.66 | 47 | 62 | 37 |
| Stochkendahl | Hard physical exercise at least once a week | Standardized examination protocol | 42 | 60 | 70 | 130 | 0.38 | 0.68 | 0.41 | 0.65 | 1.19 | 0.91 | 37 | 41 | 35 |
| Stochkendahl | Pain not provoked during a meal | Standardized examination protocol | 109 | 170 | 3 | 20 | 0.97 | 0.11 | 0.39 | 0.87 | 1.09 | 0.25 | 37 | 39 | 13 |
| Stochkendahl | Not sudden debut | Standardized examination protocol | 53 | 31 | 59 | 159 | 0.47 | 0.84 | 0.63 | 0.73 | 2.90 | 0.63 | 37 | 63 | 27 |
| Bosner | Pain >24 h | Interdisciplinary consensus | 158 | 139 | 407 | 508 | 0.28 | 0.79 | 0.53 | 0.56 | 1.30 | 0.92 | 47 | 54 | 45 |
| Stochkendahl | Age ≤49 years old | Standardized examination protocol | 67 | 54 | 45 | 136 | 0.60 | 0.72 | 0.55 | 0.75 | 2.10 | 0.56 | 37 | 55 | 25 |
| Bosner | Pain mostly at noon time | Interdisciplinary consensus | 13 | 30 | 552 | 617 | 0.02 | 0.95 | 0.31 | 0.53 | 0.50 | 1.02 | 47 | 31 | 48 |
| Bosner | Cough | Interdisciplinary consensus | 31 | 129 | 534 | 518 | 0.06 | 0.80 | 0.19 | 0.49 | 0.28 | 1.18 | 47 | 20 | 51 |
| Bosner | Known IHD | Interdisciplinary consensus | 56 | 122 | 509 | 525 | 0.10 | 0.81 | 0.32 | 0.51 | 0.52 | 1.11 | 47 | 32 | 50 |
| Bosner | Pain worse with breathing | Interdisciplinary consensus | 138 | 123 | 427 | 524 | 0.24 | 0.81 | 0.53 | 0.55 | 1.28 | 0.93 | 47 | 53 | 45 |
| Manchikanti | Chronic thoracic pain: lidocaine injection | Bupivacaine injection | 22 | 14 | _ | _ | | | 0.61 | _ | | | | | |
| Psychiatric | |||||||||||||||
| Kuijpers | Anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A score, cut-off ≥8) | Diagnosis Anxiety disorders (Mini International Neuropsychiatric Interview (gold standard)) | 195 | 71 | 3 | 75 | 0.98 | 0.51 | 0.73 | 0.96 | 2.03 | 0.03 | 58 | 73 | 4 |
| Demiryoguran | Palpitation | Anxiety disorder: HADS-A score (cut-off ≥10) | 18 | 25 | 31 | 80 | 0.37 | 0.76 | 0.42 | 0.72 | 1.54 | 0.83 | 31 | 41 | 27 |
| Demiryoguran | Fear of dying | Anxiety disorder: HADS-A score (cut-off ≥10) | 11 | 6 | 38 | 102 | 0.22 | 0.94 | 0.65 | 0.73 | 4.04 | 0.82 | 31 | 65 | 27 |
| Demiryoguran | Light-headedness, dizziness, faintness | Anxiety disorder: HADS-A score (cut-off ≥10) | 11 | 8 | 38 | 100 | 0.22 | 0.93 | 0.58 | 0.73 | 3.03 | 0.84 | 31 | 58 | 28 |
| Demiryoguran | Chills or hot flushes | Anxiety disorder: HADS-A score (cut-off ≥10) | 11 | 5 | 38 | 103 | 0.22 | 0.95 | 0.69 | 0.73 | 4.85 | 0.81 | 31 | 69 | 27 |
| Demiryoguran | Shortness of breath | Anxiety disorder: HADS-A score (cut-off ≥10) | 13 | 22 | 36 | 86 | 0.27 | 0.80 | 0.37 | 0.71 | 1.30 | 0.92 | 31 | 37 | 29 |
| Demiryoguran | Nausea or gastric discomfort | Anxiety disorder: HADS-A score (cut-off ≥10) | 9 | 10 | 40 | 98 | 0.18 | 0.91 | 0.47 | 0.71 | 1.98 | 0.90 | 31 | 47 | 29 |
| Demiryoguran | Diaphoresis | Anxiety disorder: HADS-A score (cut-off ≥10) | 19 | 12 | 30 | 96 | 0.39 | 0.89 | 0.61 | 0.76 | 3.49 | 0.69 | 31 | 61 | 24 |
| Foldes-Busque | The Panic Screening Score (derivation population) | Panic disorder diagnosis (structured Anxiety Disorders Interview Schedule for | 53 | 19 | 31 | 98 | 0.63 | 0.84 | 0.74 | 0.76 | 3.89 | 0.44 | 42 | 74 | 24 |
| Foldes-Busque | The Panic Screening Score (validation population) | Panic disorder diagnosis (structured ADIS-IV) | 69 | 27 | 61 | 148 | 0.53 | 0.85 | 0.72 | 0.71 | 3.44 | 0.55 | 43 | 72 | 29 |
| Katerndahl | GP diagnosis of panic disorder | Panic disorder (structured clinical Interview of | 2 | 2 | 26 | 21 | 0.07 | 0.91 | 0.50 | 0.45 | 0.82 | 1.02 | 55 | 50 | 55 |
| Fleet | Panic disorder diagnosis: formula including Agoraphobia Cognitions QA, Mobility Inventory for Agoraphobia, Zone 12 Dermatome Pain Map, Sensory McGill Pain QA, Gender, Zone 25 (Validation population) | Panic Disorder (ADIS-R structured interview by psychologist) | 32 | 41 | 17 | 122 | 0.65 | 0.75 | 0.44 | 0.88 | 2.60 | 0.46 | 23 | 44 | 12 |